126 related articles for article (PubMed ID: 38251734)
1. Disparities in the Receipt of Systemic Treatment in Metastatic Melanoma.
Kakish H; Pawar O; Bhatty M; Doh S; Mulligan KM; Rothermel LD; Bordeaux JS; Mangla A; Hoehn RS
Am J Clin Oncol; 2024 May; 47(5):239-245. PubMed ID: 38251734
[TBL] [Abstract][Full Text] [Related]
2. Association of health insurance with outcomes in adults ages 18 to 64 years with melanoma in the United States.
Amini A; Rusthoven CG; Waxweiler TV; Jones BL; Fisher CM; Karam SD; Raben D
J Am Acad Dermatol; 2016 Feb; 74(2):309-16. PubMed ID: 26670715
[TBL] [Abstract][Full Text] [Related]
3. Racial and Socioeconomic Disparities in the Delivery of Immunotherapy for Metastatic Melanoma in the United States.
Haque W; Verma V; Butler EB; Teh BS
J Immunother; 2019; 42(6):228-235. PubMed ID: 30985445
[TBL] [Abstract][Full Text] [Related]
4. Association of Sociodemographic Factors With Immunotherapy Receipt for Metastatic Melanoma in the US.
Moyers JT; Patel A; Shih W; Nagaraj G
JAMA Netw Open; 2020 Sep; 3(9):e2015656. PubMed ID: 32876684
[TBL] [Abstract][Full Text] [Related]
5. Socioeconomic status and survival for patients with melanoma in the United States: an NCDB analysis.
Sitenga JL; Aird G; Ahmed A; Walters R; Silberstein PT
Int J Dermatol; 2018 Oct; 57(10):1149-1156. PubMed ID: 29736922
[TBL] [Abstract][Full Text] [Related]
6. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
7. Association of Receipt of Systemic Treatment for Melanoma With Insurance Type in North Carolina.
Adamson AS; Jackson BE; Baggett CD; Thomas NE; Haynes AB; Pignone MP
Med Care; 2023 Dec; 61(12):829-835. PubMed ID: 37708348
[TBL] [Abstract][Full Text] [Related]
8. Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study.
Qian DC; Kleber T; Brammer B; Xu KM; Switchenko JM; Janopaul-Naylor JR; Zhong J; Yushak ML; Harvey RD; Paulos CM; Lawson DH; Khan MK; Kudchadkar RR; Buchwald ZS
Lancet Oncol; 2021 Dec; 22(12):1777-1786. PubMed ID: 34780711
[TBL] [Abstract][Full Text] [Related]
9. Disparities of Immunotherapy Utilization in Patients with Stage III Cutaneous Melanoma: A National Perspective.
Al-Qurayshi Z; Crowther JE; Hamner JB; Ducoin C; Killackey MT; Kandil E
Anticancer Res; 2018 May; 38(5):2897-2901. PubMed ID: 29715114
[TBL] [Abstract][Full Text] [Related]
10. Racial differences in time to treatment for melanoma.
Tripathi R; Archibald LK; Mazmudar RS; Conic RRZ; Rothermel LD; Scott JF; Bordeaux JS
J Am Acad Dermatol; 2020 Sep; 83(3):854-859. PubMed ID: 32277971
[TBL] [Abstract][Full Text] [Related]
11. Improved Survival with Immunotherapy but Lack of Synergistic Effect with Radiation for Stage IV Melanoma of the Head and Neck.
Babcock B; Rodrigues M; Kearns D; Solomon N; Reeves ME; Senthil M; Garberoglio CA; Namm JP
Am Surg; 2019 Oct; 85(10):1118-1124. PubMed ID: 31657306
[TBL] [Abstract][Full Text] [Related]
12. Survival outcomes in an older US population with advanced melanoma and central nervous system metastases: SEER-Medicare analysis.
Sadetsky N; Hernandez A; Wallick CJ; McKenna EF; Surinach A; Colburn DE
Cancer Med; 2020 Sep; 9(17):6216-6224. PubMed ID: 32667719
[TBL] [Abstract][Full Text] [Related]
13. Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control.
Alvarez-Breckenridge C; Giobbie-Hurder A; Gill CM; Bertalan M; Stocking J; Kaplan A; Nayyar N; Lawrence DP; Flaherty KT; Shih HA; Oh K; Batchelor TT; Cahill DP; Sullivan R; Brastianos PK
Oncologist; 2019 May; 24(5):671-679. PubMed ID: 30796152
[TBL] [Abstract][Full Text] [Related]
14. Treatment Contraindications Based on Comorbidity Status in Patients With Melanoma in the United States.
Boczar D; Bagaria SP; Spaulding AC; Huayllani MT; Avila FR; Guliyeva G; Lu X; Rinker BD; Forte AJ
Anticancer Res; 2021 Apr; 41(4):2067-2070. PubMed ID: 33813415
[TBL] [Abstract][Full Text] [Related]
15. Association Between Hospital Volume, Therapy Types, and Overall Survival in Stage III and IV Cutaneous Malignant Melanoma.
Tella SH; Kommalapati A; Ganti AK; Marr AS
J Natl Compr Canc Netw; 2019 Nov; 17(11):1334-1342. PubMed ID: 31693989
[TBL] [Abstract][Full Text] [Related]
16. Association of Insurance Status With Presentation, Treatment, and Survival in Melanoma in the Era of Immune Checkpoint Inhibitors.
Jain V; Venigalla S; Reddy VK; Lukens JN; Mitchell TC; Shabason JE
J Immunother; 2020 Jan; 43(1):8-15. PubMed ID: 31498180
[TBL] [Abstract][Full Text] [Related]
17. Use of immunotherapy and surgery for stage IV melanoma.
Molina G; Kasumova GG; Qadan M; Boland GM
Cancer; 2020 Jun; 126(11):2614-2624. PubMed ID: 32157676
[TBL] [Abstract][Full Text] [Related]
18. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.
McQuade JL; Daniel CR; Hess KR; Mak C; Wang DY; Rai RR; Park JJ; Haydu LE; Spencer C; Wongchenko M; Lane S; Lee DY; Kaper M; McKean M; Beckermann KE; Rubinstein SM; Rooney I; Musib L; Budha N; Hsu J; Nowicki TS; Avila A; Haas T; Puligandla M; Lee S; Fang S; Wargo JA; Gershenwald JE; Lee JE; Hwu P; Chapman PB; Sosman JA; Schadendorf D; Grob JJ; Flaherty KT; Walker D; Yan Y; McKenna E; Legos JJ; Carlino MS; Ribas A; Kirkwood JM; Long GV; Johnson DB; Menzies AM; Davies MA
Lancet Oncol; 2018 Mar; 19(3):310-322. PubMed ID: 29449192
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy Treatment Disparities: A Texas Cancer Registry Analysis of Patients with Cutaneous Melanoma.
Ramirez F; Alvarado L; Dwivedi A; Chacon J
J Immigr Minor Health; 2024 Feb; 26(1):23-33. PubMed ID: 37615821
[TBL] [Abstract][Full Text] [Related]
20. Prolonged overall survival following metastasectomy in stage IV melanoma.
Elias ML; Behbahani S; Maddukuri S; John AM; Schwartz RA; Lambert WC
J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1719-1725. PubMed ID: 31070816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
